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To evaluate the recurrence of a bladder tumor on the prostate fossa and bladder neck in patients undergoing
simultaneous transurethral resection of a bladder tumor (TUR-BT) and benign prostatic hyperplasia (BPH) in
ourhospital,we retrospectively studied fourpatientswhounderwent simultaneousTUR-BTand transurethral
resection of the prostate (TUR-P) in 2001 to 2004. The pathology was conﬁrmed histologically to be transi-
tional cell carcinomaof the bladder tissue or atypia cells andBPH. Twopatients had bladder tumor recurrence
at 18 and 33months during the postoperative follow-upperiod (10e36months,with amean of 18.5months).
One at the bladder neck recurred 33 months postoperatively, and the other in the trigone area, near the
bladder neck, recurred after 18 months. After another TUR-BT, there were no more recurrences in these two
patients. No tumor progressed to the invasive stage. Tumor recurrence on simultaneous TUR-BT and TUR-P
patients is a key issue of concern. We present a brief history of the four patients and a literature review. We
concluded that conducting the two procedures simultaneously is clinically feasible for selected patients.
Copyright  2012, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
There is a high recurrence rate for bladder tumors in patients
who have undergone transurethral resection of a bladder tumor
(TUR-BT), with rates of around 50% to 70% and 60% to 70% re-
ported.1,2 Simultaneous TUR-BT and transurethral resection of the
prostate (TUR-P) is still controversial; the possibility of tumor cell
implantation in denuded areas of the prostate gland and especially
high intravesical pressure during the proceduremake simultaneous
TUR-BT and TUR-P a hazardous procedure. However, a recent study
from South Korea emphasized that the coexistence of bladder
outlet obstruction with a non-muscle invasive bladder tumor may
have a negative cancer prognostic effect.3 As their data showed,
decreasing the postvoiding volume may reduce the risk of bladder
mucosal exposure to carcinogens. Thus we retrospectively studied
the aspect of tumor recurrence of our patients that had undergone
simultaneous TUR-P and TUR-BT in Taiwan.
2. Case reports
During 2001 to 2004, there were four patients who underwent
simultaneous TUR-P and TUR-BT (Table 1), for which the pathologytment of Surgery, Shin-Kong
n District, Taipei 111, Taiwan.
ang).
ciation. Published by Elsevier Taiwshowed nodular hyperplasia and transitional cell carcinoma (TCC)
of the bladder tumor. Brief histories are given as follows.
2.1. Case 1
A 79-year-old man with underlying chronic obstructive
pulmonary disease was admitted due to acute urinary retention
with hematuria. A Foley catheter was put in place in the outpatient
department. A transrectal ultrasound of the prostate (TRUS-P)
showed the prostate volume to be about 20 ml. An incidental
ﬁnding was made of a bladder tumor 1 cm in diameter located in
the left lateral wall during TUR-P. He underwent simultaneous TUR-
BT and TUR-P. The pathology report indicated WHO Grade 2 TCC.
The clinical stage was T1N0M0, and 10 g of prostate tissue were
resected. Mitomycin-C was instilled in the bladder once weekly for
6 weeks postoperatively. No tumor recurrence was noted during
a 22-month follow-up period.
2.2. Case 2
An 80-year-old man had symptoms of painless hematuria and
a bladder tumor conﬁrmed by a cystoscopic examination. Following
TUR-BT, the pathology report indicated a single nonmuscle invasive
bladder TCC of about 3 cm in diameter located in the trigone. Pelvic
computed tomography showed clear perivesical fat and noan LLC. Open access under CC BY-NC-ND license.
Table 1
Demographic characteristics of the four patients.
Patient
no.
Age
(years)
Follow-up
interval
(months)
Muscle
invasion
Grade Location Tumor
size
(cm)
Time to recurrence
(months)
Recurrence at
the same site
Recurrence at the
prostate fossa/bladder neck
1 79 22 Negative 2 Left lateral wall, single 1 Negative no no
2 80 33 Negative e Trigone near bladder neck Sessile, 2 33 yes yes
3 74 18 Negative 2 Posterior wall and bladder neck Sessile, 1 18 yes no
4 53 12 Positive 3 Anterior wall 2 Negative no no
Table 2
Tumor recurrence after simultaneous transurethral resection of a bladder tumor
(TUR-BT) and of the prostate (TUR-P), or TUR-BT alone.
Group Simultaneous TUR-BT and TURP TUR-BT alone
No. of
patients (n)
# ## No. of
patients (n)
# ##
Ozgur et al 31 11 1 34 14 1
Vicente et al 100 55 10 100 73 10
Won et al 106 31 0 107 46 0
Our series 4 2 1
Total 241 99 12 241 133 11
# Tumor recurrence anywhere; ## tumor recurrence at the bladder neck or prostate
fossa.
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He underwent simultaneous TUR-P and TUR-BT 3 months later due
to persistent frequency and nocturia, and also suspected local
tumor recurrence. Thirteen grams of prostate tissue were resected.
The pathology of the urinary bladder specimen at that time was
atypical cells with hyperplasia. No adjuvant chemotherapy was
administered. He was regularly followed-up every 3 months, and
recurrence at the same site near the bladder neck was found 33
months postoperatively. TUR-BT was done a third time, and no
tumor recurrence was found in 6 years of follow-up.
2.3. Case 3
A 74-year-old man had painless gross hematuria, and TCC of the
urinary bladder was conﬁrmed by a cystoscopic examination. He
underwent TUR-BT, and the pathology report indicated a non-
muscle invasive bladder tumor located at the posterior wall and
bladder neck. The pathology report showed a WHO Grade 2 tumor
at that time. Sessile tumor recurrence at the bladder neck was
suspected during a cystoscopic examination at two sites near the
bladder neck; they were about 1 cm in diameter. He also com-
plained of nocturia and frequency. TRUS-P showed that the prostate
volume was 43 ml, with dominant intravesical growth. He under-
went simultaneous TUR-P and TUR-BT; the pathology report
showed low-grade TCC. The clinical stage was T1N0M0, and 40 g of
prostate tissue were resected. No adjuvant chemotherapy was
given. A tumor mass recurrence at the bladder neck (the same site)
was suspected 18 months later. He underwent TUR-BT again, and,
during 3 years of follow-up, no tumor recurrence was evident.
2.4. Case 4
A 53-year-old man complained several times of painless gross
hematuria. Urine cytology suggested amalignancy, and intravenous
pyelography revealed a tumor mass in the left anterior wall of the
urinary bladder and a vesicle stone. A whole-body positron emis-
sion tomographic scan was done due to reduced body weight, and
a mediastinal mass, 8 cm in diameter, was found. Uroﬂowmetry
showed a low ﬂow rate (maximum ﬂow rate of 6.2 ml/s). He
underwent simultaneous TUR-P, cystolithotripsy, and TUR-BT, and
a solitary tumormass was found in the left anterior wall. Five grams
of prostate tissue were resected. The pathology report indicated
WHO Grade 3 TCC with smooth muscle invasion. The tumor stage
was T2NxMx. He then underwent a thymus biopsy, which showed
a malignant thymoma. Intravesical instillation with mitomycin-C
was done six times postoperatively. In a 12-month follow-up
period, no tumor mass recurred. Radical surgery was not con-
ducted; instead concurrent chemoradiotherapy was given for the
malignant thymoma.
3. Discussion
The high recurrence rate of bladder tumors after undergoing
TUR-BT, the possibility of tumordissemination during the procedure,and the denuded surface of the prostate after TUR-P make simulta-
neous TUR-BT and TUR-P a hazardous procedure.4
Ugurlu et al reported on 34 patients who underwent TUR-BT
alone and 31 patients who underwent simultaneous TUR-P and
TUR-BT, and showed one patient with recurrence in the prostate
fossa or bladder neck in each group.4 Vicente et al reported on 100
patients who underwent TUR-BT alone and 100 patients who
underwent simultaneous TUR-P and TUR-BT, and showed 10
patients with prostate fossa or bladder neck recurrence in each
group.5 Thus, their data showed no meaningful inﬂuence on tumor
recurrence in the prostate fossa between the group with TUR-BT
alone and the group with simultaneous TUR-P and TUR-BT. Won
et al prospectively studied 107 cases with TUR-BT only and 106
cases with simultaneous TUR-BT and TUR-P. The tumor character-
istics, including grade, size, and multiplicity, showed no difference
between the two groups. After a mean follow-up period of more
than 50 months in each group, they showed that neither tumor
multiplicity nor size inﬂuenced the recurrence rate between the
two groups; however, patients with a solitary tumor had a lower
recurrence rate in the simultaneous TUR-BT and TUR-P group,
which may have been due to the release of bladder outlet
obstruction, possibly reducing the postvoiding volume.3 The data
from the three studies are shown in Table 2. The overall recurrence
rates in the simultaneous group and control group were 41% and
55%, respectively, while the prostatic and bladder neck recurrence
rates were 4.6% in the simultaneous group and 4.5% in the control
group. Tsivian et al retrospectively studied 51 patients who
underwent simultaneous TUR-P and TUR-BT. Their patients were
divided into two groups according to whether there were single
tumors (28 cases) or multiple tumors (23 cases). There were 35
patients with tumor recurrence, and a higher recurrence rate and
shorter time to recurrencewere seen in themultiple bladder cancer
group. There were 11 patients with bladder neck or prostatic
urethral recurrence, and only one clear-cut tumor recurrence was
found in a prostate surgery-related site. There was synchronous
and metachronous tumor recurrence at other bladder sites in the
other 10 patients with bladder neck or prostatic fossa recurrence.
They suggested that tumormulticentricity favors tumor recurrence,
but instrumental manipulation does not.6
Golomb et al studied 36 patients who underwent a simultaneous
transvesical prostatectomy and TUR-BT. They had 23 recurrent
C.-H. Lee et al. / Urological Science 23 (2012) 31e33 33patients with six patients (over 25%) with recurrence in
prostatectomy-related sites. They divided their patients into high-
and low-grade groups, and a higher recurrence ratewas found in the
high-grade group (83%) than the low-grade group (60%). Thus,
tumor recurrence at the prostatectomy location may be related to
the combined procedures.7
In our series, Case 1 had a solitary bladder tumor of <3 cm in
diameter thatwas incidentally foundduringTUR-P, although TUR-BT
alone is deemed to have a low risk of recurrence. After simultaneous
TUR-P and TUR-BT, no tumor recurrence was found. Cases 2 and 3
had tumor recurrence at the bladder neck and original site, respec-
tively. Although they had undergone a simultaneous operation for
BPH and a vesicle tumor, no recurrence was found at the prostate
fossa. Case 4 had a severe bladder outlet obstruction and a vesicle
stone. Although the malignant thymoma was the major entity, no
obvious tumor mass recurrence was seen during follow-up.
Simultaneous TUR-BT and TUR-P still remain controversial,
especially for tumors with multicentricity, which are thought to
have a higher recurrence rate, according to the previous literature.
Since this surgical approach has still not been proven to affect
tumor recurrence negatively, according to our experience and
a literature review, it may be suggested that simultaneous TUR-P
and TUR-BT are considered clinically feasible as a selective proce-
dure for low-risk patients.Conﬂicts of interest statement
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